ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 113 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,261,238 | +47819.4% | 187,964 | -36.9% | 0.00% | -100.0% |
| Q1 2023 | $2,632 | -67.2% | 298,041 | -71.6% | 0.00% | -50.0% |
| Q4 2022 | $8,013 | -99.9% | 1,048,869 | +32.5% | 0.00% | +33.3% |
| Q3 2022 | $5,638,000 | +5.9% | 791,824 | +20.4% | 0.00% | 0.0% |
| Q2 2022 | $5,322,000 | -35.0% | 657,833 | +11.5% | 0.00% | -25.0% |
| Q1 2022 | $8,187,000 | +93.0% | 589,825 | +290.1% | 0.00% | +100.0% |
| Q4 2021 | $4,242,000 | +170.7% | 151,185 | +227.9% | 0.00% | +100.0% |
| Q3 2021 | $1,567,000 | +26.3% | 46,107 | +51.8% | 0.00% | 0.0% |
| Q2 2021 | $1,241,000 | -38.9% | 30,372 | -39.8% | 0.00% | 0.0% |
| Q1 2021 | $2,030,000 | -71.3% | 50,416 | -57.8% | 0.00% | -80.0% |
| Q4 2020 | $7,071,000 | +1082.4% | 119,586 | +497.9% | 0.01% | +400.0% |
| Q4 2019 | $598,000 | -88.7% | 20,000 | -88.3% | 0.00% | -87.5% |
| Q3 2019 | $5,284,000 | -84.5% | 171,018 | -75.8% | 0.01% | -84.3% |
| Q2 2019 | $34,171,000 | – | 707,467 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $23,152,516 | 15.55% |
| BERYLSON CAPITAL PARTNERS, LLC | 289,726 | $2,213,507 | 6.45% |
| Matrix Capital Management Company, LP | 11,572,590 | $88,414,588 | 1.69% |
| Pier Capital, LLC | 1,012,401 | $7,734,744 | 1.27% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $229,151,929 | 1.15% |
| Eagle Health Investments LP | 607,860 | $4,644,050 | 1.07% |
| Triatomic Management LP | 130,805 | $999,350 | 0.84% |
| Aristotle Atlantic Partners, LLC | 1,880,567 | $14,367,532 | 0.80% |
| Senator Investment Group LP | 1,000,000 | $7,640,000 | 0.69% |
| ARK Investment Management | 9,201,245 | $70,297,512 | 0.61% |